About this Journal Submit a Manuscript Table of Contents

Biomarkers for Prostate Cancer

Call for Papers

Prostate cancer is the most common noncutaneous cancer in men in the developed countries and is increasing in incidence in the developing countries. With the recent recognition of PSA screening as controversial, the diagnosis and treatment of prostate cancer are faced with new challenges and led to new efforts in biomarker discovery to improve diagnosis, prognosis, and treatment of prostate cancer.

Thus, we invite authors to submit original research and review articles that address urological problems with a focus on the Urologic Oncology. Articles published in this special issue are of interest to researchers and clinicians involved in the practice of prostate. The special issue will become an international forum for researchers and clinicians to summarize the most recent developments, advances in techniques, instrumentation, surgery, and ideas in the field, with a special emphasis given to the technical and observational results obtained within the last five years. Potential topics include, but are not limited to:

  • Biomarkers for diagnosis, prognosis, and/or treatment of Prostate Cancer
  • Epigenetics in prostate cancer
  • Tumor microenvironment in prostate cancer
  • Tumor stem cell in prostate cancer
  • Bioinformatics and Biostatistics applied to prostate cancer research
  • Next generation sequencing applied to prostate cancer research

Before submission authors should carefully read over the journal’s Author Guidelines, which are located at http://www.hindawi.com/journals/bmri/guidelines/. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://mts.hindawi.com/submit/journals/bmri/urology/bpc/ according to the following timetable:

Manuscript DueFriday, 2 May 2014
First Round of ReviewsFriday, 25 July 2014
Publication DateFriday, 19 September 2014

Lead Guest Editor

  • Chung Lee, Department of Urology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Guest Editors

  • Ralph Buttyan, Department of Urologic Sciences, The University of British Columbia, Vancouver, BC, Canada
  • Leland W. K. Chung, Uro-Oncology Research Program, Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • Louis Denis, Europa Uomo, Lange Gasthuisstraat, Antwerp, Belgium
  • Zhenyu Jia, Department of Statistics, University of Akron, Akron, OH, USA